Beihai Gofar Chuanshan Biological (600538.SH) director Wu Peicheng plans to spend 2 to 4 million yuan to increase holdings.

19/01/2025

GMT Eight

Beihai Gofar Chuanshan Biological (600538.SH) announced that Mr. Wu Peicheng, a director of the company, plans to increase his shareholding in the company through concentrated trading starting from January 20, 2025 for a period of 6 months. The amount of increase shall not be less than 2 million yuan and not exceed 4 million yuan.

CITIC SEC: China's cosmetics industry entering a stage of healthy growth, focusing on the group and global development of domestic brands.

Shenzhen Changhong Technology (300151.SZ) issued a profit forecast, with an expected annual net profit of 90 million to 120 million yuan, a year-on-year increase of 184.31% to 279.09%.

Contact: contact@gmteight.com

Beihai Gofar Chuanshan Biological (600538.SH) director Wu Peicheng plans to spend 2 to 4 million yuan to increase holdings.

RECOMMEND

New Stock Preview | Core product prices and quantities are falling simultaneously + Debt ratio reaches 84%, cannot stop Rongda Hezhong's distribution exceeding net profit.

Sinopharm (01099): China National Accord Medicines Corporation (000028.SZ) is expected to have a net profit attributable to shareholders of approximately 561 million to 760 million yuan in 2024, a year-on-year decrease of 52.48% to 64.92%.

China Securities Co., Ltd.: AI application in B-end commercialization landing, OA/ERP as the entry-level platform will benefit first.